Targeted drug delivery platform company Phoenix Solutions AS is awarded 16 MNoK (1.8 M€) from the Research Council of Norway.

CEO Per Sontum is pleased to announce that the company has been granted this significant award under the RCN BIA call:

This funding will enable us to push on with our project to fight pancreatic cancer and meet a key developmental milestone; execution of a clinical phase I/IIa program from mid-2018

Previous
Previous

Jean-Claude Provost (MD) elected to the BoD

Next
Next

Phoenix Solutions AS completes its Series A financing.